Atreca, Dana-Farber to study mechanisms of cancer immunotherapy

Atreca Inc. (Redwood City, Calif.) and Dana-Farber Cancer Institute (Boston, Mass.) partnered to study active immune response in cancer patients who respond to immunotherapy. The partners will use Atreca’s Immune Repertoire Capture technology to study how immunotherapies generate active immune response; explore why only a subset of cancer patients respond to different therapies; and identify anti-tumor antibodies generated in the response. The technology identifies and generates sequences of antibodies and T cell receptors associated with immune response...